Clinical and Quality of Life Benefits for End-Stage Workers' Compensation Chronic Pain Claimants following H-Wave(R) Device Stimulation: A Retrospective Observational Study with Mean 2-Year Follow-Up
| dc.contributor.author | Trinh, Alan | |
| dc.contributor.author | Williamson, Tyler K. | |
| dc.contributor.author | Han, David | |
| dc.contributor.author | Hazlewood, Jeffrey E. | |
| dc.contributor.author | Norwood, Stephen M. | |
| dc.contributor.author | Gupta, Ashim | |
| dc.date.accessioned | 2023-02-10T14:28:44Z | |
| dc.date.available | 2023-02-10T14:28:44Z | |
| dc.date.issued | 2023-02-01 | |
| dc.date.updated | 2023-02-10T14:28:45Z | |
| dc.description.abstract | Previously promising short-term H-Wave(R) device stimulation (HWDS) outcomes prompted this retrospective cohort study of the longer-term effects on legacy workers' compensation chronic pain claimants. A detailed chart-review of 157 consecutive claimants undergoing a 30-day HWDS trial (single pain management practice) from February 2018 to November 2019 compiled data on pain, restoration of function, quality of life (QoL), and polypharmacy reduction into a summary spreadsheet for an independent statistical analysis. Non-beneficial trials in 64 (40.8%) ended HWDS use, while 19 (12.1%) trial success charts lacked adequate data for assessing critical outcomes. Of the 74 final treatment study group charts, missing data points were removed for a statistical analysis. Pain chronicity was 7.8 years with 21.6 ± 12.2 months mean follow-up. Mean pain reduction was 35%, with 89% reporting functional improvement. Opioid consumption decreased in 48.8% of users and 41.5% completely stopped; polypharmacy decreased in 36.8% and 24.4% stopped. Zero adverse events were reported and those who still worked usually continued working. An overall positive experience occurred in 66.2% (p < 0.0001), while longer chronicity portended the risk of trial or treatment failure. Positive outcomes in reducing pain, opioid/polypharmacy, and anxiety/depression, while improving function/QoL, occurred in these challenging chronic pain injury claimants. Level of evidence: III | |
| dc.description.department | Management Science and Statistics | |
| dc.identifier | doi: 10.3390/jcm12031148 | |
| dc.identifier.citation | Journal of Clinical Medicine 12 (3): 1148 (2023) | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12588/1708 | |
| dc.rights | Attribution 4.0 United States | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | H-Wave® | |
| dc.subject | electrotherapy | |
| dc.subject | neurostimulation | |
| dc.subject | quality of life | |
| dc.subject | functional status | |
| dc.subject | pain reduction | |
| dc.subject | chronic pain | |
| dc.subject | opioids | |
| dc.subject | polypharmacy | |
| dc.subject | workers’ compensation | |
| dc.title | Clinical and Quality of Life Benefits for End-Stage Workers' Compensation Chronic Pain Claimants following H-Wave(R) Device Stimulation: A Retrospective Observational Study with Mean 2-Year Follow-Up | |
| dc.type | Article |